169 related articles for article (PubMed ID: 23390206)
1. Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus.
Bagaglio S; Messina E; Uberti-Foppa C; Merli M; Torre LD; Lazzarin A; Hasson H; Morsica G
J Antimicrob Chemother; 2013 Jun; 68(6):1448-50. PubMed ID: 23390206
[No Abstract] [Full Text] [Related]
2. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
[TBL] [Abstract][Full Text] [Related]
4. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.
Lisboa-Neto G; Noble CF; Pinho JR; Malta FM; Gomes-Gouvêa MS; Alvarado-Mora MV; da Silva MH; Leite AG; Piccoli LZ; Rodrigues FK; Carrilho FJ; Mendes-Correa MC
Antivir Ther; 2015; 20(3):281-7. PubMed ID: 25279715
[TBL] [Abstract][Full Text] [Related]
5. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
6. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
[TBL] [Abstract][Full Text] [Related]
8. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
Colson P; Gérolami R
J Infect Dis; 2011 May; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
[No Abstract] [Full Text] [Related]
9. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
[TBL] [Abstract][Full Text] [Related]
10. Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors.
Colson P; Purgus R; Borentain P; Gérolami R
J Clin Virol; 2012 Feb; 53(2):178-80. PubMed ID: 22079973
[No Abstract] [Full Text] [Related]
11. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
[TBL] [Abstract][Full Text] [Related]
12. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
[TBL] [Abstract][Full Text] [Related]
13. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
[TBL] [Abstract][Full Text] [Related]
14. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Palanisamy N; Danielsson A; Kokkula C; Yin H; Bondeson K; Wesslén L; Duberg AS; Lennerstrand J
Antiviral Res; 2013 Jul; 99(1):12-7. PubMed ID: 23648709
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus NS3 mutations in haemophiliacs.
Lin MV; Charlton AN; Rouster SD; Zamor PJ; Sherman KE
Haemophilia; 2014 Sep; 20(5):659-65. PubMed ID: 24697920
[TBL] [Abstract][Full Text] [Related]
17. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
[TBL] [Abstract][Full Text] [Related]
19. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.
Morsica G; Bagaglio S; Uberti-Foppa C; Galli L; Lazzarin A
J Acquir Immune Defic Syndr; 2009 May; 51(1):106-8. PubMed ID: 19390331
[No Abstract] [Full Text] [Related]
20. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
Treviño A; de Mendoza C; Parra P; Rodríguez C; Madejón A; Plaza Z; del Romero J; Poveda E; Soriano V
Antivir Ther; 2011; 16(3):413-6. PubMed ID: 21555824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]